Quantification of circulating CRT in rat and human sera. Levels of CRT in rat sera (a) were measured by ELISA, revealing that CRT in EAE animals (n=5) was significantly (p<0.05) less than that in control animals (n=5). Testing for CRT in human sera (b) revealed significantly increased CRT in human MS sera (p<0.05), n=14) when compared to healthy controls (n=11). When data from MS samples was separated (c) according to whether or not individuals were undergoing treatment with nataluzimab, CRT was still significantly higher (p<0.01) in non-nataluzimab-treated patients (n=5), compared to samples from healthy controls (n=11). There was no significant difference in levels found in individuals on nataluzimab when compared to CRT in healthy controls.